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Abstract
Background: Conversion from calcineurin inhibitor (CNI) therapy to everolimus within 6 months after kidney
transplantation improves long-term graft function but can increase the risk of mild biopsy-proven acute cellular
rejection (BPAR). We performed a post-hoc analysis of histological data from a randomized trial in order to further
analyze histologic information obtained from indication and protocol biopsies up to 5 years after transplantation.
Methods: Biopsy samples obtained up to 5 years post-transplant were analyzed from the randomized ZEUS study,
in which kidney transplant patients were randomized at month 4.5 to switch to everolimus (n = 154) or remain on
cyclosporine (CsA)-based immunosuppression (n = 146). All patients received mycophenolate and steroids.
Results: At least one investigator-initiated biopsy was undertaken in 53 patients in each group between
randomization and year 5, with a mean (SD) of 2.6 (1.7) and 2.2 (1.4) biopsies per patient in the everolimus
and CsA groups, respectively. In the everolimus and CsA groups, investigator-initiated biopsies showed (i)
BPAR in 12.3 and 7.5% (p = 0.182) of patients, respectively, with episodes graded mild in 22/24 and 18/20
cases (ii) CsA toxicity lesions in 4.5 and 10.3% of patients (p = 0.076) (iii) antibody-mediated rejection in 0.6
and 2.7% of patients (p = 0.204), respectively.
Conclusions: This analysis of histological findings in the ZEUS study to 5 years after kidney transplantation
shows no increase in antibody-mediated rejection under everolimus-based therapy with a lower rate of
CNI-related toxicity compared to a conventional CsA-based regimen, and confirms the preponderance of
mild BPAR seen in the main study after the early switch to CsA-free everolimus therapy.
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Background
Long-term graft survival is the key objective when deter-
mining the immunosuppressive regimen after kidney trans-
plantation. The graft, however, is subject to multiple insults
which can ultimately lead to irreversible nephron loss and
progressive dysfunction, but this typically occurs relatively
late such that graft function is a poor marker for the sever-
ity of histological changes. These include early tubulointer-
stitial damage from ischemia-reperfusion injury, acute and
subclinical rejection, calcineurin inhibitor (CNI)-related
nephrotoxicity, and viral infections [1]. Up to 1 year post-
transplant, subclinical rejection is found in 30–50% of
stable grafts in patients treatment with cyclosporine
(CsA) [2], and in up to 15% of patients receiving tacrolimus
[3–6], and is associated with subsequent tubulointerstitial
damage [7, 8]. Subsequently, chronic microvascular and
glomerular damage caused by interstitial fibrosis/tubular
atrophy (IF/TA) becomes more common, affecting 50% of
grafts by 2 years despite normal graft function [7, 8]. IF/TA
is associated with reduced survival, particularly in the
presence of inflammation [9].
Minimizing exposure to CNI therapy is a well-established
strategy to limit pathophysiological damage to the graft [1].
Use of mammalian target of rapamycin (mTOR) inhibitors
to facilitate pre-emptive CNI withdrawal after the initial
post-transplant phase achieves a significant improvement
in short- and long-term renal function versus a conven-
tional CNI-based regimen if the conversion takes place by
month 6 [10–13]. In two randomized trials, however, there
was a significant [10] or numerical [13] increase in the rate
of mild biopsy-proven acute cellular rejection (BPAR). The
improved renal function during follow-up to as much
as 5 years post-transplant is highly encouraging. High
donor-specific antibody (DSA) values in a cohort of patients
switched from CNI to everolimus have been reported in one
single-center analysis [14], potentially increasing the risk for
acute humoral rejection. Histological data from patients
randomized to a CNI-free immunosuppressive regimen
versus CNI-based long-term therapy would provide
further insights into whether humoral mechanisms are
relevant for pathological injury in these grafts.
Five-year follow-up data have recently been reported from
the ZEUS study, in which kidney transplant patients were
randomized at month 4.5 to switch to the mTOR inhibitor
everolimus or remain on CsA-based immunosuppression
[11]. The results showed significantly improved renal func-
tion in the everolimus-treated cohort at 5 years versus con-
trols. BPAR occurred in 13.6 and 7.5% of patients in the
everolimus and CsA cohorts, respectively (p = 0.095), with
the difference in BPAR rates largely accounted for by
grade I rejection [11]. In the ZEUS trial, graft biopsies
were requested at baseline, month 12 post-transplant,
and as clinically mandated. We report here a detailed
analysis of the full pathology findings from the study
biopsies, including the presence of CNI-related toxicity,
antibody-mediated rejection (AMR) and chronic/scler-
osing allograft nephropathy.
Methods
Study design and patient population
ZEUS was a 12-month multicenter, open-label, parallel-
group trial in which kidney transplant recipients were
randomized at 4.5 months post-transplant to convert to
everolimus or remain on CsA therapy (NCT00154310).
After completion of the 12-month study visit, patients
were followed up at annual observational visits during an
extension phase of the study until 5 years post-transplant.
The study was undertaken at 17 transplant centers in
Germany and Switzerland during June 2005 to September
2007, with the final five-year visit in September 2012. The
study was conducted in compliance with Good Clinical
Practice and the Declaration of Helsinki.
The study population comprised recipients of a kidney
transplant aged 18–65 years. Key exclusion criteria at
the time of transplantation were more than one previous
renal transplantation, loss of previous graft due to immuno-
logical reasons in the first year post-transplant, multiple
organ transplantation (e.g. kidney and pancreas), receipt of
an organ donated after cardiac death, donor age < 5 years
or > 65 years, historical or current peak panel reactive
antibodies (PRA) > 25%, platelets < 75,000/mm3 with an
absolute neutrophil count of < 1500/mm3 or leucocytes
< 2500/mm3, hemoglobin < 6 g/dl, or severe liver disease.
Key inclusion criteria at 4.5 months post-transplant (the
point of randomization) were treatment with CsA, enteric-
coated mycophenolate sodium (EC-MPS, minimum dose
of 720 mg/day) and corticosteroids, and serum creatinine
≤265 μmol/l. Key exclusion criteria at month 4.5 post-
transplant were graft loss, previous rejection that was
severe (Banff grade ≥ II), recurrent or steroid-resistant,
dialysis dependency or proteinuria > 1 g/day.
Immunosuppression
All patients received basiliximab induction therapy
(Simulect®, Novartis Pharma AG, Basel, Switzerland).
Until month 4.5, the immunosuppression regimen com-
prised CsA (Sandimmun® Optoral/Neoral®, Novartis Pharma
AG) dosed according to pre-specified target ranges for
trough concentration and concentration at 2 hours
post-dose [10], 1440 mg/day EC-MPS (Myfortic®, Novartis
Pharma AG) and corticosteroids according to local
practice.
At 4.5 months post-transplant, patients were stratified
according to living or deceased donor and randomized
using an automated, validated system. For patients ran-
domized to the everolimus group, everolimus was initiated
and CsA was withdrawn in a stepwise manner over a max-
imum of 4 weeks. The everolimus target C0 concentration
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was 6–10 ng/ml following CsA discontinuation. For
patients randomized to continue CsA therapy, CsA dosing
was adjusted according to tapered target ranges to month
12. After the month 12 study visit, the assigned immuno-
suppressive regimen was to be maintained but changes
were permitted at any time based on each patient’s clinical
needs at the discretion of the investigator.
Graft biopsies
Protocol biopsies were requested at time of transplant,
the point of randomization (month 4.5) and at month 12.
The study protocol also stipulated that graft core biopsies
were to be performed in the event of a suspected rejection
episode prior to (or at the latest within 24 h after) the
initiation of anti-rejection therapy. If there was an inad-
equate response to a full course of steroids and initiation
of antilymphocyte therapy was delayed for more than
10 days after the diagnosis of BPAR, a repeat biopsy
was to be performed to confirm ongoing rejection.
Biopsies were read and interpreted by a local patholo-
gist, the results of which were used without histological
re-evaluation for the current analysis. Data were cap-
tured in response to the following questions: Is there
any histological evidence of acute/active rejection (with
Banff grading)?; Is there any histological evidence of
chronic/sclerosing allograft nephropathy (with Banff
grading)?; Is there any evidence of AMR (severity
graded as acute tubular necrosis [ATN]-like/minimal
inflammation, capillary marginal and/or thrombosis, arterial
v3 [transmural inflammation/fibrinoid change])?; Is C4d
staining positive?; Presence of other lesions/abnormal
findings (borderline lesions, ATN, acute allograft glomeru-
lopathy, calcineurin toxicity lesions, donor lesions, chronic
allograft glomerulopathy, other)? Follow-up biopsies are
reported for all patients up to 5 years post-transplant.
Data analysis
Data were analyzed from biopsies performed at the time
of randomization or thereafter in the core or extension
phases of the study. Biopsies undertaken in response to
a clinical event, or as follow-up to a clinical event, were
categorized as ‘investigator-initiated’ and were analyzed
separately from protocol-specified biopsies performed at
(i) randomization or (ii) month 12 or at the point of early
study discontinuation. Pathological findings according to
Banff 97 criteria [15] and information on C4d staining
are presented. The presence of CNI toxicity was defined
according to local histopathology criteria. Histological
changes characteristic of AMR are itemized. The final
clinical diagnoses for all cases in which rejection was
suspected and an investigator-initiated biopsy was under-
taken are presented.
Data on rejection episodes were recorded during the
12-month study and at each annual follow-up visit up to
5 years post-transplant. The final clinical diagnoses of
rejection events were captured up to 5 years post-trans-
plant according to the following categories on the case
report form: normal; infection; acute cellular rejection
diagnosed by biopsy; acute and chronic rejection; recur-
rence of original disease; infarction/thrombosis; tech-
nical problem; post-transplant lymphoproliferative
disorder; urinary obstruction; delayed graft function;
acute tubular necrosis; urological problem; calcineurin
inhibitor induced toxicity; chronic allograft nephropathy;
borderline lesions; other.
The incidence of biopsy findings is presented per
treatment group using two different denominators: (i)
the number of patients with ≥1 biopsy (ii) the number of
patients in the intent-to-treat (ITT) population. Between-
group differences were compared using the T-test (two-
sided), Fisher’s test (two-sided) or Chi square test where
appropriate.
Results
Patient population and study treatment
The ITT population included 300 patients (everolimus
154, CsA 146). The 12-month core study was completed by
269 patients (138 everolimus, 131 CsA) and the five-year
visit was attended by 232 patients (123 everolimus, 109
CsA) (Additional file 1: Figure S1). The characteristics of
recipients and donors were similar between treatment
groups other than body mass index, which was higher in
the everolimus group (Additional file 1: Table S1). By year 5
post-transplant, 45.2% of patients randomized to everoli-
mus remained on everolimus in a CNI-free regimen. In the
CsA group, 58.6% of patients were still receiving CsA and a
further 11 patients (7.6%) had switched to tacrolimus so
remained on CNI therapy (Additional file 1: Table S2). For
the patients in whom data were available regarding used of
steroid therapy, 79/123 patients in the everolimus group
(64.2%) and 70/109 patients in the CsA group (64.2%) were
receiving steroids at 5 years post-transplant.
Biopsy samples
Protocol biopsies were performed in 40 patients (13.3%
of patients; 22 everolimus, 18 CsA) at randomization
and in 34 patients (11.3% of patients; 17 everolimus, 17
CsA) at month 12. Prior to randomization at month 4.5,
investigator-initiated biopsies were performed in 125
patients (41.7%), at a mean of 0.9 months post-transplant
(Table 1). In total, 178 investigator-initiated biopsies were
performed after randomization, in 53 everolimus-treated
patients (34.4%) and 53 CsA-treated patients (36.3%), of
which 67 (67/178, 37.6%) were obtained by year 1 and 111
(111/178, 62.4%) were obtained during years 2–5 (Table 1).
The mean (SD) number of investigator-initiated biopsies
per patient between randomization and year 5 was 2.6
(1.7) in the everolimus group compared to 2.2 (1.4) in the
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CsA group, at a mean of 20.2 (16.6) and 19.5 (15.8) months
post-transplantation, respectively.
An additional 54 biopsy samples (34 everolimus, 20 CsA)
in 26 patients (15 everolimus, 11 CsA) were provided but
were inadequately categorized regarding reason for biopsy
(i.e. protocol-mandated or investigator-initiated) and were
excluded from analyses. Results from these samples are
shown in Additional file 1: Table S3.
Pathology findings
Protocol biopsies
Protocol biopsy results at randomization and at month
12 revealed few cases of clinically undetected mild BPAR
or other lesions in either treatment group, but the number
of such biopsies was low (Table 2).
Investigator-initiated biopsies prior to randomization
In the 125 patients who underwent biopsy prior to
randomization, BPAR was present in 28 cases (22.4%), the
majority of which were grade 1A (Table 2). CNI-related
lesions (n = 37) and acute tubular necrosis (n = 36) were
more frequently observed than BPAR. AMR was rare
(4/125, 3.2%).
Investigator-initiated biopsies after randomization
Among patients in whom post-randomization investigator-
initiated biopsies were performed between randomization
and year 5, BPAR was detected in 19 everolimus-treated
patients (19/154, 12.3%; 10 episodes of grade 1A, 6 grade
1B, 6 grade 2A, 1 grade 3 [1 missing]) and 11 CsA-treated
patients (11/146, 7.5%; 8 episodes of grade 1A, 1 grade 1B,
2 grade 2A, 2 grade 3) (p = 0.182) (Table 2). The incidence
from randomization to year 1 was 8.4% (13/154) versus
3.4% (5/146) in everolimus and CsA groups, respectively
(p = 0.088), and 5.8% (9/154) versus 4.8% (7/146) during
the extension phase (years 2–5) (p = 0.799). The severity of
BPAR between randomization and year 5 was comparable
between groups, with 22/24 episodes of BPAR in the
everolimus group and 18/20 episodes in the CsA group
graded mild (grade ≤ 2A).
The proportion of patients exhibiting chronic/sclerosing
allograft nephropathy on investigator-initiated biopsies
after randomization was 7.1% in the everolimus group and
8.2% in the CsA group (p = 0.829), and was graded mild
(Banff grade ≤ 2A) in the majority of cases (Table 2).
Borderline lesions occurred with similar frequency in
each group (p = 0.680). Pathologists reported CNI toxicity
lesions in 7/154 (4.5%) and 15/146 (10.3%) of patients
undergoing investigator-initiated biopsies in the everolimus
and CsA groups, respectively (p = 0.076).
Post-randomization, AMR was detected in one
everolimus-treated patient (0.6%) which was categorized
as ATN-like and was C4d positive. Four CsA-treated
patients developed AMR (2.7%): two showed ATN-like
changes (both C4d positive), one had arterial-v3 changes
(C4d positive) and one showed capillary-marginal change/
thrombosis (C4d negative). C4d staining was detected in
17 everolimus-treated patients (11.0%) and 10 CsA-treated
patients (6.8%), including one of the three patients in the
everolimus group who developed AMR and three of the
six CsA-treated patients with AMR.
When pathology diagnoses in investigator-initiated
biopsy samples after randomization were compared as a
proportion of patients undergoing biopsy, there was a
higher rate of ‘other’ lesions in the everolimus cohort
(50.9% versus 26.4%, p = 0.016) and a non-significant
trend (p = 0.092) to a higher rate of CNI-related toxicity
lesions in the CsA arm.
Clinical diagnoses following biopsy
The final clinical diagnosis among patients with one or
more investigator-initiated biopsy after randomization
performed in response to suspected rejection (everolimus
52, CsA 50) is summarized in Table 3.
Table 1 Graft biopsies to year 5 post-transplant
Everolimus
(n = 154)
CsA
(n = 146)
Number of patients with protocol-specified biopsies, n (%)
Randomization n (%) 22 (14.3) 18 (12.3)
Month 12, n (%) 17 (11.0) 17 (11.6)
Number of patients with investigator-initiated biopsies, n (%)
Before randomization 61 (39.6) 64 (43.8)
After randomization
Core phase (to year 1) 27 (17.5) 26 (17.8)
Extension phase (years 2–5) 39 (25.3) 34 (23.3)
Total 53 (34.4) 53 (36.3)
Total number of investigator-initiated biopsies, n
Before randomization 111 115
After randomization
Core phase 33 34
Extension phase (years 2–5) 62 49
Total 95 83
Mean (SD) number of investigator-initiated biopsies per patient, n
Before randomization 1.8 (1.0) 1.8 (1.1)
After randomization 1.8 (1.2) 1.6 (1.0)
Time from transplant to first investigator-initiated biopsy, months
Before randomization
Mean (SD) 0.9 (0.9) 0.9 (0.9)
Median (range) 0.4 (0.2–3.7) 0.5 (0.2–4.2)
After randomization
Mean (SD) 19.5 (15.8) 20.2 (16.6)
Median (range) 10.5 (4.3–59.5) 13.3 (30.5–59.6)
CsA cyclosporine, SD standard deviation
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Table 2 Pathology assessment of biopsies according to Banff criteria
No. events % based on number of patients with ≥1 biopsy % based on number of ITT patients
Protocol-specified biopsies, n (%) Everolimus CsA Everolimus CsA P valuea
Biopsy at randomization 22 18 n = 22 n = 18 – –
BPAR grade 1A 1 0 4.5 0 1.000 –
Borderline lesions 4 3 18.2 16.7 1.000
Other 1 1 4.5 5.6 1.000
Month 12 17 17 n = 17 n = 17 –
BPAR, any 3 1 17.6 5.9 0.601 –
Grade 1A 0 1
Grade 1B 1 0
Grade 2A 2 0
Chronic/sclerosing allograft nephropathy
Grade 1 1 1 5.9 5.9 1.000
CNI toxicity lesions 1 0 5.9 0 1.000
Borderline lesions 3 1 17.6 5.9 0.601
Investigator-initiated biopsy, n (%)b Everolimus CsA Everolimus N = 61 CsA N = 64 P valuea Everolimus N = 154 CsA N= 146 P valuea
Before randomization 61 64 n = 61 n = 64 – 39.6 43.8 –
BPAR, any 11 17 18.0 26.6 0.288 7.1 11.6 0.234
Grade 1A 9 7
Grade 1B 0 2
Grade 2A 1 0
Grade 2B 0 2
Grade 3 0 0
Grade missing 1 7
Antibody-mediated rejection 2 2 3.3 3.1 1.000 1.3 1.4 1.000
Chronic/sclerosing allograft
nephropathy
2 2 3.3 3.1 1.000 1.3 1.4 1.000
Grade 1 1 1
Grade 2 1 1
Grade 3 0 0
CNI toxicity lesions 17 20 27.9 31.3 0.700 11.0 13.7 0.489
Borderline lesions 9 15 14.8 23.4 0.260 5.8 10.3 0.202
Acute tubular necrosis 15 21 24.6 32.8 0.300 9.7 14.4 0.286
Chronic allograft glomerulopathy 0 1 0 1.6 1.000 0 0.7 0.487
Donor lesions 4 6 6.6 9.4 0.744 2.6 4.1 0.533
Other 16 21 26.2 32.8 0.440 10.4 14.4 0.380
After randomization 53 53 n = 53 n = 53 – 34.4 36.3 –
BPAR, any 19 11 35.8 20.8 0.131 12.3 7.5 0.182
Grade 1A 10 8
Grade 1B 6 1
Grade 2A 6 2
Grade 2B 0 0
Grade 3 1 2
Grade missing 1 0
Antibody-mediated rejection 1 4 1.9 7.5 0.363 0.6 2.7 0.204
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Discussion
Clinically-indicated renal biopsies from the randomized
ZEUS study up to year 5 post-transplant showed a trend
to more frequent mild acute cellular rejection, and approxi-
mately half the incidence of CNI-toxicity lesions, under an
everolimus-based regimen with early CNI elimination ver-
sus standard CsA therapy. The between-group differences
were not statistically significant, however, in the relatively
small cohort of patients undergoing clinically-indicated
biopsy after randomization. The severity of acute cellular
rejection and rates of AMR and chronic allograft nephrop-
athy were similar between groups following randomization.
Consistent with this, the proportion of patients in whom a
post-randomization biopsy was requested was also com-
parable with everolimus- or CsA-based treatment.
The surveillance biopsies which were requested in the
study protocol at randomization and month 12 were
performed in only a low proportion of patients, severely
limiting interpretation. There was a numerically higher
number of BPAR and borderline lesions in the everolimus
group, but these were each observed in only three patients
versus one patient in the CsA group, so conclusions
cannot be drawn.
AMR was rare in both treatment arms after
randomization (everolimus 0.6%, CsA 2.7%). The diagnosis
was made based only on histological changes with or with-
out C4d staining [15], since, at that time, DSAs were not
measured in most centers during the study. A subsequent
protocol amendment specified that data on DSA levels
should be collected at the five-year study visit, but this was
provided for only 28 patients in the everolimus group and
25 patients in the CsA group, and, in this subset of
patients, no difference was found between treatment groups
[11]. In the recent CENTRAL study, which randomized
Table 2 Pathology assessment of biopsies according to Banff criteria (Continued)
No. events % based on number of patients with ≥1 biopsy % based on number of ITT patients
Chronic/sclerosing allograft
nephropathy
11 12 20.8 22.6 1.000 7.1 8.2 0.829
Grade 1 7 7
Grade 2 2 4
Grade 3 2 3
CNI toxicity lesions 7 15 13.2 28.3 0.092 4.5 10.3 0.076
Borderline lesions 14 11 26.4 20.8 1.000 9.1 7.5 0.680
Acute tubular necrosis 2 1 3.8 1.9 1.000 1.3 0.7 1.000
Chronic allograft glomerulopathy 7 4 13.2 7.5 0.526 4.5 2.7 0.543
Donor lesions 0 2 0 3.8 0.495 0 1.4 0.236
Other 27 14 50.9 26.4 0.016 17.5 9.6 0.063
aFisher’s exact test (two-sided)
bMore than one biopsy was performed in some patients, so more than one grade per patient could be specified
BPAR biopsy-proven acute cellular rejection, CNI calcineurin inhibitor, CsA cyclosporine, ITT intent-to-treat
Table 3 Final clinical diagnosis following a post-randomization investigator-initiated biopsy in response to suspected rejectiona
No. events % based on number of patients with ≥1 suspected
rejection
% based on number of ITT patients
Everolimus CsA Everolimus N = 52 CsA N = 50 P valueb Everolimus N = 154 CsA N = 146 P valueb
Acute cellular rejectionc 17 26 32.7 52.0 0.071 11.0 17.8 0.102
Acute & chronic rejection 1 2 1.9 4.0 0.614 0.6 1.4 0.614
Borderline lesions 17 17 32.7 34.0 1.000 11.0 11.6 1.000
CNI-induced toxicity 14 14 26.9 28.0 1.000 9.1 9.6 1.000
Acute tubular necrosis 4 6 7.7 12.0 0.521 2.6 4.1 0.533
Chronic allograft nephropathy 9 9 17.3 18.0 1.000 5.8 6.2 1.000
Infection 0 3 0 6.0 0.114 0 2.1 0.114
Normal 13 10 25.0 20.0 0.638 8.4 6.8 0.668
Other 23 20 44.2 40.0 0.692 14.9 13.7 0.869
aMore than one clinical diagnosis was possible
bFisher's exact test (two-sided)
cIncludes diagnosis made in advance of biopsy results (everolimus 2, CsA 1)
CNI calcineurin inhibitor, CsA cyclosporine
Eisenberger et al. BMC Nephrology  (2018) 19:154 Page 6 of 8
kidney transplant patients at week 7 to switch to everolimus
or remain on CsA, DSA was detected in 15.0% of patients
in the everolimus group (9/60 patients) and 21.1% in the
CsA arm (12/57 patients) (p = 0.600) [16].
The incidence of CNI-induced toxicity based on histo-
logical analysis was approximately twice as high in the CsA
cohort as in those switched to everolimus, but the absolute
difference was relatively small (4.5% versus 10.3%). This is
perhaps not unexpected since it is accounted for by the fact
that the first investigator-initiated biopsy was performed at
approximately 20 months post-transplant in both groups.
The histological lesions which characterize CNI nephrotox-
icity (arteriolar hyalinosis, striped cortical fibrosis, tubular
microcalcification) develop progressively over time [17].
In a study of sequential protocol biopsies, Nankivell et
al. showed that approximately 25% of patients had
CNI-induced lesions by month 6, doubling to half of all
patients by year 5 [17], but in our series the low rate of
protocol biopsies was inadequate to offer meaningful
data on subclinical CNI-related nephrotoxicity.
Protocol-specified biopsies were requested but were
not mandatory, and were performed in accordance with
local center practice. In fact, protocol biopsies were per-
formed in only 13% of patients at randomization and in only
11% at month 12, presumably since this conflicted with local
practice. Regrettably, biopsy data from 26 patients did not
specify whether they were protocol- or clinically-mandated,
and were therefore excluded from the current analysis since
they could not reliably be assigned to a category. The
resulting small numbers preclude reliable interpretation
and negate the possibility for a matched/paired analysis. Pre-
viously, the CERTITEM study has reported a higher rate of
subclinical rejection in kidney transplant patients switched
from CNI therapy to everolimus at month 3 post-transplant
versus those who continued CNI (10.4% versus 2.0%, p =
0.015) [18]. In that trial, however, the everolimus-treated
population was under-immunosuppressed due to 50%
reduction in mycophenolic acid dose. Here, a difference
in subclinical rejection appears unlikely since there was no
indication of greater long-term histological deterioration
under everolimus based on investigator-initiated biopsies
and since renal function remained superior to the CNI
treatment group to 5 years post-transplant [11].
The ZEUS trial offered the benefit of a randomized,
multicenter study design with long-term follow-up to 5
years, and a balanced proportion of patients in each treat-
ment group providing at least one biopsy sample after
randomization. All pathological assessments were carried
out locally at the 17 participating centers to ensure rapid
information for clinical decision-making, and inevitably
this introduces the risk of variability in pathological
assessments between centers [19, 20]. There is no reason
to expect, however, that this variability influenced the
between-group comparison. Also, more than 60% of
investigator-initiated biopsies were undertaken after year 1,
offering a good comparison of the effect of the two treat-
ment regimens on graft histology over the first 5 years after
kidney transplantation. It is also important to note that
by the end of the five-year follow-up period, only 45%
of patients in the everolimus arm were still receiving
everolimus, and only 59% of those randomized to CsA
continued to receive CsA.
Clinical analyses of data from the ZEUS study at one
[10] and five [11] years post-transplant have shown super-
ior graft function after switch from CsA to everolimus
therapy, with a higher rate of mild acute cellular rejection
reported by clinicians in the everolimus cohort at year 1.
This more detailed analysis of histological findings from
the ZEUS study confirms the preponderance of early mild
BPAR cases in the CNI-free everolimus-arm as published
before [10], but with no increase in AMR and a lower
rate of CNI-related toxicity. These findings suggest that
conversion from CsA to everolimus by month 6 after
kidney transplantation, with concomitant mycophenolic
acid and steroids, can be undertaken safely and offers
the possibility to reduce CNI-related toxicity.
Additional file
Additional file 1: Table S1. Baseline characteristics (safety population).
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